去甲氧柔红霉素联合阿糖胞苷治疗初发急性髓系白血病的疗效及安全性分析

Curative Effect and Safety of Idamycin Combined with Cytarabine in Treatment of Patients with Primary Acute Myeloid Leukemia

目的探讨去甲氧柔红霉素(IDA)联合阿糖胞苷(Ara-C)治疗初发急性髓系白血病(AML)的疗效及安全性。方法选取我院血液科2015年5月—2018年5月收治的AML 60例为研究对象,根据化疗方案不同分为DA组32例和IA组28例。DA组采取柔红霉素(DNR)+Ara-C化疗,IA组采取IDA+Ara-C化疗;治疗1个疗程后观察2组的疗效和不良反应。结果 IA组完全缓解(CR)的病例数和CR+部分缓解(PR)的百分率高于DA组(P<0.05);2组化疗后血液毒副作用和非血液毒副作用比较差异无统计学意义(P>0.05)。结论 IDA联合Ara-C治疗初发AML安全、有效。

Objective To investigate curative effect and safety of Idamycin (IDA) combined with Cytarabine (Ara-C) in treatment of patients with newly acute myeloid leukemia (AML). Methods A total of 60 patients with AML admitted during May 2015 and May 2018 were divided into DA group ( n =32) and IA group ( n =28) according to different chemotherapy methods. DA group was treated with Daunorubicin (DNR) and Ara-C chemotherapy, while IA group was treated with IDA and Ara-C chemotherapy. Therapeutic effects and adverse reactions were observed after one course of treatment in two groups. Results Numbers of complete remission (CR) cases and percentage of CR+ partial remission (PR) in DA group were significantly higher than those in DA group ( P <0.05). There were no significant differences in blood and non-blood toxic and side-effects after treatment between two groups ( P >0.05). Conclusion IDA combined with Ara-C is safe and effective in treatment of patients with newly acute myeloid leukemia.